| Similar Articles |
|---|
 |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.   |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
American Family Physician
November 1, 2000
Neil Abramson & Becky Melton |
Leukocytosis: Basics of Clinical Assessment Leukocytosis, a common laboratory finding, is most often due to relatively benign conditions (infections or inflammatory processes). Much less common but more serious causes include primary bone marrow disorders... |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
American Family Physician
May 1, 2004 |
Polycythemia Vera A general overview on Polycythemia Vera, a disease in which the body makes too many red blood cells. |
Nursing
June 2011
Cahill & Armstrong |
Caring for an adult with a malignant primary brain tumor Pprimary brain tumors are relatively uncommon, occurring in an estimated 63,000 patients in the united states each year. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
February 2009
Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Nursing Management
July 2010
Lois Welden |
Transfusion confusion Over the past decade, literature has indicated that liberal use of blood transfusions results in poor clinical outcomes in the majority of critically ill patients. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Pharmaceutical Executive
January 1, 2013
Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
CIO
October 29, 2015
Martha Heller |
Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies. |
Pharmaceutical Executive
May 1, 2006
Madison, Chan & Seeger |
Making the Link The FDA recognizes that a new drug standard must evolve -- one of routine, proactive safety surveillance. But post-marketing safety studies are too slow. Here's how pharmaceuticals are using claims databases to solve the problem. |
Pharmaceutical Executive
September 1, 2012
Al Topin |
Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty. |
